At Ligand, we seek to identify high-value, risk-mitigated biopharmaceutical assets. We take a systematic and disciplined approach to investing to build a diversified portfolio of programs that produce consistent and predictable revenue streams for our shareholders.
Investment Strategies
Royalty Monetization
M&A
Project Finance
Platform Technology Acquisitions
Royalty Monetization
Royalty Monetization
We acquire existing royalty contracts from inventors, universities, and non-strategic assets from biopharmaceutical companies. Today, our portfolio consists of more than 200 different programs and includes economic rights to some of the most impactful medicines in the world.
M&A
M&A
A key part of our investment strategy is to acquire companies with valuable assets or partnerships. Through efficiency improvements and cost reduction, we can realize the underlying value of these assets through new royalty streams.
Project Finance
Project Finance
We finance biopharmaceutical programs with established proof of concept in return for a royalty contract on future sales. These programs are typically in Phase II or III of development.
Platform Technology Acquisitions
Platform Technology Acquisitions
We focus on platforms that are scalable and have broad applicability that will enable us to generate new royalty streams. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.
Asset Selection Criteria
- Strong clinical differentiation
- Addresses unmet need
- Solid patent protection
- Time to market
- Therapeutically agnostic